Biotech Values

[fink]

Gild's pricing is a bargain compared to an organ replacement. However the State's Medcaids would rather take a gamble the IV users and down and outs, will die before they get to the point of replacing an organ due to HepC.

That's the big question. Are high risk losers worth the $$?
It's selling off the shelf. Can't wait for the Q report.